Chemotherapy for osteoradionecrosis of mandible using a pentoxifylline-tocopherol-clodronate combination (PENTOCLO).

Chemotherapy for osteoradionecrosis of mandible using a pentoxifylline-tocopherol-clodronate combination (PENTOCLO). - Chemotherapy for osteoradionecrosis using PENTOCLO

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019780

Enrollment

Registered

2015-11-13

Start date

2015-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoradionecrosis of the mandible

Interventions

Pentoxifillyne 800mg/day 5 days in a week 1 year Clodoronate 1600mg/day 7 days in a week 1 year Tocopherol 1g/day 7days in a week 1 year

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Osteoradionecrosis with oral mucosal and/or skin defect with or without pus discharging.

Exclusion criteria

Exclusion criteria: A patient with gastrointestinal disease

Design outcomes

Primary

Measure	Time frame
Sequestration with oral mucosal and cutaneous healing	—

Countries

Japan

Contacts

Public ContactHirota, Makoto

Yokohama City University Oral and Maxillofacial Surgery

mhirota@yokohama-cu.ac.jp045-787-2800

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026